A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China
Cancers · 11.08.2023 · 15 (16) · 4060
DOI: 10.3390/cancers15164060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.08.2023. Verfasst von Zizhu Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Nuclear Industry Hospital, Beijing 102413, China. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Research Project of CNNC, Research Foundation of CNNCCBYI, Nuclear Medicine Innovation Project of CNNCMIC.
Abstract (Originalsprache)
Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and neutron irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by the development of compact neutron source devices. The availability, ease of operation, and cost-effectiveness offered by these compact neutron sources make BNCT more accessible to cancer treatment centers. Two compact neutron sources, one being miniature reactor-based (IHNI-1) and the other one being accelerator-based (NeuPex), have entered the clinical research phase and are planned for medical device registration. Moreover, several accelerator-based neutron source devices employing different technical routes are currently under construction, further expanding the options for BNCT implementation. In addition, the development of compact neutron sources serves as an experimental platform for advancing the development of new boron agents. Several research teams are actively involved in the development of boron agents. Various types of third-generation boron agents have been tested and studied in vitro and in vivo. Compared to other radiotherapy therapies, BNCT in mainland China still faces specific challenges due to its limited clinical trial data and its technical support in a wide range of professional fields. To facilitate the widespread adoption of BNCT, it is crucial to establish relevant technical standards for neutron devices, boron agents, and treatment protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Nuclear Industry Hospital, Beijing 102413, China.
- Beijing Capture Tech Co., Ltd., Beijing 102413, China.
- Innovation Business Center, China National Nuclear Corporation Overseas Ltd., Beijing 100044, China.
- Neuboron Therapy System Ltd., Nanjing 211100, China.
- BNCT Center, Xiamen Humanity Hospital, Xiamen 361016, China.
- College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Förderung
- Basic Research Project of CNNC
- Research Foundation of CNNCCBYI
- Nuclear Medicine Innovation Project of CNNCMIC
Zitieren
APA
Zhang, Z., Chong, Y., Liu, Y., Pan, J., Huang, C., Sun, Q., Liu, Z., Zhu, X., Shao, Y., Jin, C., & Liu, T. (2023). A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China. Cancers, 15(16), 4060. https://doi.org/10.3390/cancers15164060
Vancouver
Zhang Z, Chong Y, Liu Y, Pan J, Huang C, Sun Q, et al. A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China. Cancers. 2023;15(16):4060. doi:10.3390/cancers15164060
BibTeX
@article{Zhang2023,
author = {Zhang, Zizhu and Chong, Yizheng and Liu, Yuanhao and Pan, Jianji and Huang, Cheng and Sun, Qi and Liu, Zhibo and Zhu, Xiayang and Shao, Yujun and Jin, Congjun and Liu, Tong},
title = {A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China},
journal = {Cancers},
year = {2023},
volume = {15},
number = {16},
pages = {4060},
doi = {10.3390/cancers15164060}
}
EUVIMED